SCM
RLMD icon

Silverarc Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Silverarc Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-393,000
Closed -$14.5M – 101
2022
Q3 		$14.5M Buy
+393,000
New +$10.9M 4.92% 2

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Silverarc Capital Management's RLMD Position: Q3 2024 in Review

Silverarc Capital Management sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 99,379 shares — an estimated $298K sold.

Silverarc Capital Management first reported a position in RLMD in Q2 2021 and held it in 5 quarters. The position peaked at $462K in Q1 2024. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • Silverarc Capital Management reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 99,379 Relmada Therapeutics shares in Q3 2024, an estimated $298K.
  • Silverarc Capital Management first reported a position in Relmada Therapeutics in Q2 2021 and held it in 5 quarters.
  • Silverarc Capital Management's Relmada Therapeutics position peaked at $462K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.